Compare · GILD vs SNTI
GILD vs SNTI
Side-by-side comparison of Gilead Sciences Inc. (GILD) and Senti Biosciences Inc. (SNTI): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both GILD and SNTI operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- GILD is the larger of the two at $181.46B, about 15401.0x SNTI ($11.8M).
- Over the past year, GILD is up 32.0% and SNTI is down 73.2% - GILD leads by 105.2 points.
- GILD has been more active in the news (10 items in the past 4 weeks vs 2 for SNTI).
- GILD has more recent analyst coverage (25 ratings vs 3 for SNTI).
- Company
- Gilead Sciences Inc.
- Senti Biosciences Inc.
- Price
- $148.85+1.72%
- $0.38-2.93%
- Market cap
- $181.46B
- $11.8M
- 1M return
- +13.44%
- +10.36%
- 1Y return
- +32.04%
- -73.17%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 1992
- 2021
- News (4w)
- 10
- 2
- Recent ratings
- 25
- 3
Gilead Sciences Inc.
Gilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of human immunodeficiency virus (HIV) infection; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr; Tizona; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos; Janssen; Japan Tobacco, Inc.; Gadeta; Bristol-Myers Squibb Company; Merck; and Novo Nordisk A/S. The company was founded in 1987 and is headquartered in Foster City, California.
Latest GILD
- FDA Approval for SUNLENCA issued to GILEAD SCIENCES INC
- FDA Approval for SUNLENCA issued to GILEAD SCIENCES INC
- Director Welters Anthony exercised 18,000 shares at a strike of $61.06 and sold $2,675,220 worth of shares (18,000 units at $148.62) as part of a pre-agreed trading plan (SEC Form 4)
- SEC Form N-PX filed by Gilead Sciences Inc.
- Gilead Sciences to Present at Upcoming Third Quarter 2026 Investor Conferences
- European Commission Expands Role of Gilead’s Trodelvy® in First-Line Metastatic Triple-Negative Breast Cancer Across PD-L1 Status
- Director Bluestone Jeffrey exercised 5,000 shares at a strike of $67.04 and sold $725,078 worth of shares (5,000 units at $145.02) as part of a pre-agreed trading plan (SEC Form 4)
- Chief Financial Officer Dickinson Andrew D sold $415,080 worth of shares (3,000 units at $138.36) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 165,646 units (SEC Form 4)
- Chief Comm & Corp Aff Officer Mercier Johanna exercised 25,000 shares at a strike of $67.07 and sold $3,853,908 worth of shares (28,000 units at $137.64) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 118,234 units (SEC Form 4)
- EVP Gen Counsel, Legal & Comp Cain Wettan Keeley M covered exercise/tax liability with 2,908 shares and converted options into 6,002 shares, increasing direct ownership by 58% to 8,454 units (SEC Form 4)
Latest SNTI
- SEC Form DEFA14A filed by Senti Biosciences Inc.
- Senti Biosciences Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation
- SEC Form PREM14A filed by Senti Biosciences Inc.
- Amendment: SEC Form S-3/A filed by Senti Biosciences Inc.
- SEC Form DEFA14A filed by Senti Biosciences Inc.
- Senti Biosciences Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Results of Operations and Financial Condition, Changes in Control of Registrant, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
- Senti Biosciences Holdings, Inc. Announces a Strategic Transaction to Unlock Value for its Gene-Circuit-Enabled Pipeline, Including SENTI-202, and to Sharpen its Focus on Next-Generation Controllable Genetic Medicines Powered by its Regulator Dial™ Technology Platform
- The Radoff-JEC Group Releases Presentation Highlighting Why Seer, Inc. Stockholders Should Vote for Boardroom Change
- SEC Form S-3 filed by Senti Biosciences Inc.
- Senti Biosciences Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits